Quinolinyl and benzothiazolyl modulators
AssigneeTularik Inc.
InventorsLawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ. In particular, the compounds of the invention modulate the function of PPARγ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
Claims38
A compound having the formula (I):
- 188
- wherein
- Ar1 is a member selected from the group consisting of substituted or unsubstituted 2-benzothiazolyl and substituted or unsubstituted quinolinyl;
- X is selected from the group consisting of —O—, —C(O)—, —CH(R10)—, —N(R11)—, and —S(O)k—,
- wherein
- R10 is a member selected from the group consisting of hydrogen, cyano and (C1-C4)alkyl;
- R11 is a member selected from the group consisting of hydrogen and (C1-C8)alkyl, and the subscript k is an integer of from 0 to 2;
- with the proviso that when Ar1 is a substituted or unsubstituted 2-benzothiazolyl, then X is other than —S(O)k—;
- Y is —N(R12)—S(O)2—,
- wherein
- R12 is a member selected from the group consisting of hydrogen and (C1-C8)alkyl;
- R1 is a member selected from the group consisting of hydrogen, (C2-C8)heteroalkyl, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, —C(O)R14, —CO2R4, —C(O)NR15R16, —S(O)p—R14, —S(O)q—NR15 R16, —O—C(O)—R17 and —N(R14)—C(O)—R17;
- wherein
- R4 is a member selected from the group consisting of hydrogen, (C1-C8)alkyl, (C2-C8)heteroalkyl, aryl and aryl(C1-C4)alkyl;
- R15 and R16 are members independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C2-C8)heteroalkyl, aryl, and aryl(C1-C4)alkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;
- R17 is a member selected from the group consisting of (C1-C8)alkyl, (C2-C8)heteroalkyl, aryl and aryl(C1-C4)alkyl;
- the subscript p is an integer of from 0 to 3;
- and
- the subscript q is an integer of from 1 to 2;
- R2 is substituted or unsubstituted aryl;
- and
- R3 is a member selected from the group consisting of halogen and (C1-C8)alkoxy.
25 A method in accordance with claim 20, wherein said metabolic disorder is selected from the group consisting of diabetes, obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, hypertriglylceridemia, hyperglycemia, insulin resistance and hyperinsulinemia.
Dependencies are inferred from the claim text.